A prospective multicenter trial on nonmyeloablative allogeneic stem cell transplantation (NST) for poor-risk chronic lymphocytic leukemia (CLL):: Final results of the GCLLSG CLL3X study

被引：0
|
作者：
Dreger, P. [1 ,2 ]
Stilgenbauer, S. [2 ]
Boettcher, S. [2 ]
Ritgen, M. [2 ]
Busch, R. [2 ]
Bunjes, D. [2 ]
Beelen, D. [2 ]
Cohen, S. [2 ]
Hegenbart, U. [1 ]
Schubert, J. [2 ]
Hertenstein, B. [2 ]
Stadler, M. [2 ]
Glass, B. [2 ]
Burchert, A. [2 ]
Uharek, L. [2 ]
Basara, N. [2 ]
Humpe, A. [2 ]
Duehrsen, U. [2 ]
Hallek, M. [2 ]
Schmitz, N. [2 ]
Kneba, M. [2 ]
Doehner, H. [2 ]
机构：
[1] Univ Heidelberg, Heidelberg, Germany
[2] German CLL Study Grp, Cologne, Germany
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [1] Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study)
    Dreger, Peter
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Ritgen, Matthias
    Dietrich, Sascha
    Bunjes, Donald
    Beelen, Dietrich Wilhelm
    Cohen, Sandra
    Hegenbart, Ute
    Schubert, Joerg
    Stadler, Michael
    Glass, Bertram
    Burchert, Andreas
    Uharek, Lutz
    Hallek, Michael
    Kneba, Michael
    Schmitz, Norbert
    Doehner, Hartmut
    [J]. BLOOD, 2008, 112 (11) : 212 - 212
  • [2] Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial
    Scheffold, Annika
    Jebaraj, Billy Michael Chelliah
    Jaramillo, Sonia
    Tausch, Eugen
    Steinbrecher, Daniela
    Hahn, Michael
    Boettcher, Sebastian
    Ritgen, Matthias
    Bunjes, Donald
    Zeis, Matthias
    Stadler, Michael
    Uharek, Lutz
    Scheid, Christoph
    Hegenbart, Ute
    Hallek, Michael
    Kneba, Michael
    Schmitz, Norbert
    Doehner, Hartmut
    Dreger, Peter
    Stilgenbauer, Stephan
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (02) : 342 - 346
  • [3] Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial
    Scheffold, Annika
    Jebaraj, Billy Michael Chelliah
    Tausch, Eugen
    Boettcher, Sebastian
    Ritgen, Matthias
    Bunjes, Donald
    Zeis, Matthias
    Stadler, Michael
    Uharek, Lutz
    Scheid, Christof
    Hegenbart, Ute
    Hallek, Michael
    Kneba, Michael
    Schmitz, Norbert
    Doehner, Hartmut
    Dreger, Peter
    Stilgenbauer, Stephan
    [J]. BLOOD, 2014, 124 (21)
  • [4] Long-term disease control of poor-risk chronic lymphocytic leukemia (CLL) by allogeneic stem cell transplantation with nonmyeloablative conditioning (NST):: Interim results of a prospective study
    Dreger, P
    Stilgenbauer, S
    Boettcher, S
    Bunjes, D
    Ottinger, H
    Beelen, D
    Cohen, S
    Schubert, J
    Hertenstein, B
    Basara, N
    Humpe, A
    Ritgen, M
    Zeis, M
    Schmitz, N
    Hallek, M
    Kneba, M
    Döhner, H
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 43 - 44
  • [5] Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
    Dreger, Peter
    Doehner, Hartmut
    Ritgen, Matthias
    Boettcher, Sebastian
    Busch, Raymonde
    Dietrich, Sascha
    Bunjes, Donald
    Cohen, Sandra
    Schubert, Joerg
    Hegenbart, Ute
    Beelen, Dietrich
    Zeis, Matthias
    Stadler, Michael
    Hasenkamp, Justin
    Uharek, Lutz
    Scheid, Christof
    Humpe, Andreas
    Zenz, Thorsten
    Winkler, Dirk
    Hallek, Michael
    Kneba, Michael
    Schmitz, Norbert
    Stilgenbauer, Stephan
    [J]. BLOOD, 2010, 116 (14) : 2438 - 2447
  • [6] Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial
    Zenz, Thorsten
    Dreger, Peter
    Dietrich, Sascha
    Boettcher, Sebastian
    Ritgen, Matthias
    Winkler, Dirk
    Buehler, Andreas
    Bunjes, Donald
    Beelen, Dietrich
    Cohen, Sandra
    Hegenbart, Ute
    Zeis, Matthias
    Hallek, Michael
    Kneba, Michael
    Schmitz, Norbert
    Doehner, Hartmut
    Stilgenbauer, Stephan
    [J]. BLOOD, 2010, 116 (21) : 974 - 975
  • [7] Early autologous stem cell transplantation (SCT) in genetically poor-risk chronic lymphocytic leukemia is feasible and effective: Results from a prospective multicenter study (GCLLSG CLL3 protocol).
    Dreger, P
    Busch, R
    Stilgenbauer, S
    Greinix, H
    Hensel, M
    Hertenstein, B
    Duehrsen, U
    Hentrich, M
    Truemper, LH
    Schmitz, N
    Ritgen, M
    Emmerich, B
    Hallek, MJ
    Kneba, M
    Dohner, H
    [J]. BLOOD, 2004, 104 (11) : 45A - 45A
  • [8] Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial
    M Ritgen
    S Böttcher
    S Stilgenbauer
    D Bunjes
    J Schubert
    S Cohen
    A Humpe
    M Hallek
    M Kneba
    N Schmitz
    H Döhner
    P Dreger
    [J]. Leukemia, 2008, 22 : 1377 - 1386
  • [9] Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia:: results from the GCLLSG CLL3X trial
    Ritgen, M.
    Boettcher, S.
    Stilgenbauer, S.
    Bunjes, D.
    Schubert, J.
    Cohen, S.
    Humpe, A.
    Hallek, M.
    Kneba, M.
    Schmitz, N.
    Doehner, H.
    Dreger, P.
    [J]. LEUKEMIA, 2008, 22 (07) : 1377 - 1386
  • [10] QUANTITATIVE MRD MONITORING IDENTIFIES DISTINCT GVL RESPONSE PATTERNS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS FROM THE GCLLSG CLL3X TRIAL
    Dreger, P.
    Boettcher, S.
    Stilgenbauer, S.
    Bunjes, D.
    Schubert, J.
    Cohen, S.
    Hallek, M.
    Kneba, M.
    Dobner, H.
    Ritgen, M.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 62 - 62
12345